Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab

Overview of attention for article published in Annals of Surgical Oncology, January 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 13 X users

Readers on

mendeley: 2 Mendeley

So far, Altmetric has seen 15 X posts from 13 X users, with an upper bound of 268,997 followers.

RT @theNCI: Should response to #immunotherapy before surgery dictate the selection of immunotherapy after surgery for patients with #melano…

RT @EmilyVerbus: We're starting our skin cancer clinical trial spotlight looking at different treatment regimens for #melanoma previously t…

RT @theNCI: Should response to #immunotherapy before surgery dictate the selection of immunotherapy after surgery for patients with #melano…

We're starting our skin cancer clinical trial spotlight looking at different treatment regimens for #melanoma previously treated with #immunotherapy. Check it out! @AnnSurgOncol @JMHernandez_MD

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 11 additional X posts.